News
Projects
Orgs
Project
Articles 71
Votes 0
FiercePharma

Authors 7

FiercePharma
Zoey Becker
Kevin Dunleavy
Max Bayer
Angus Liu
Nick Paul Taylor
Fraiser Kansteiner
The Ad Council teams up with the Alzheimer's Association for Hispanic dementia awareness push - FiercePharma
>2y
FDA signs off on J&J's prostate cancer combo therapy Akeega - FiercePharma
>2y
As sales crater, Moderna sees hope in private COVID vaccine market and RSV launch - FiercePharma
>2y
Pfizer unveils potential cost-cutting measure on low COVID sales - FiercePharma
>2y
AstraZeneca forecasts stronger China sales as CEO tries to clear the air on spinoff report - FiercePharma
>2y
GSK's Arexvy to lead new RSV vaccines sales race with Moderna a close second: report - FiercePharma
>2y
Pfizer, FDA right the ship at tornado-hit NC production plant - FiercePharma
>2y
Novartis to buy back $15B in shares despite Entresto setback - FiercePharma
>2y
Merck applies more pressure against IRA, asking for decision without trial in fight with US government - FiercePharma
>2y
Pfizer, Opko gain FDA nod for weekly growth hormone drug Ngenla - FiercePharma
>2y
GSK and Pfizer RSV shots under CDC scrutiny, with vote today - FiercePharma
almost3y
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med - FiercePharma
almost3y
Novo takes action against unlawful sales of Ozempic, Wegovy - FiercePharma
almost3y
After metastatic disease win, Merck's Keytruda flunks trial in early stomach cancer - FiercePharma
almost3y
Game on, AbbVie. Roche's Columvi nabs FDA nod as 2nd bispecific for large B-cell lymphoma - FiercePharma
almost3y
ASCO: Enhertu delivers 'very compelling' pan-tumor activity - FiercePharma
almost3y
ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma - FiercePharma
almost3y
PhRMA cries foul on CMS' registry approach for Alzheimer's drugs - FiercePharma
almost3y
PhRMA cries foul on CMS' registry approach for Alzheimer's drugs - FiercePharma
almost3y
Carrying blockbuster sales expectations, BMS' Camyzos picks up early nod from England's NICE - FiercePharma
almost3y
AZ, Merck's Lynparza wins FDA nod in prostate cancer subgroup following advisory committee vote - FiercePharma
almost3y
With a tepid recommendation, NICE signs off on Pfizer's Vydura - FiercePharma
almost3y
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers - FiercePharma
almost3y
FDA clears Braeburn's long-acting Brixadi to treat opioid use disorder - FiercePharma
almost3y
Blueprint's Ayvakit picks up long-awaited label expansion - FiercePharma
almost3y